A Phase I/II Placebo-Controlled Randomized Pilot Clinical Trial of Recombinant Deoxyribonuclease (DNase) Eye Drops Use in Patients With Dry Eye Disease.

Transl Vis Sci Technol · 2019 · PMC6504128 · PMID 31110911

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

In the DNase group, the median reduction in OSDI (−20.75) was more than placebo group (−8.43); however, the difference between groups was borderline significant.

also in 11,409 other papers

borderline significanceno p-value reported

The OSDI score showed a median reduction of 13.9, which is minimal clinically important difference (MCID), but the change between week 8 and baseline showed a borderline significance.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.